Type 1 Diabetes Management With Technology: Patterns of Utilization and Effects on Glucose Control Using Real-World Evidence
In this medfyle
CGM plus CSII in newly diagnosed T1D may translate into long-term control.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Expert commentary
Acknowledgements
This Medfyle is provided as a service to healthcare professionals. It has been created from content originally published in Clinical Diabetes®, an official journal of the American Diabetes Association®, and is published in coordination with Sheridan. This MedFyle was created by GlobalPort (International) Limited with permission from the American Diabetes Association; neither Sheridan nor the American Diabetes Association takes any responsibility for its accuracy or for the use of any content therein by those reading or downloading such content.
The summary content was prepared by Marie Farrow for Medfyle, reviewed & approved by Dr. Banshi Saboo, MD, MNAMS, Msc-endocrine (UK), PhD, Diabetologist-Endocrine & Metabolic Physician, Ahmedabad - India
Original article:
Sun R, Banerjee I, Sang S, Joseph J, Schneider J, Hernandez-Boussard T. Type 1 Diabetes Management With Technology: Patterns of Utilization and Effects on Glucose Control Using Real-World Evidence. Clin Diabetes. 2021 Jul;39(3):284-292. doi: 10.2337/cd20-0098. PMID: 34421204; PMCID: PMC8329015.
The authors of the original article had no part in the creation of the summary.
All Medfyle content, summaries, expert commentaries and slides are owned by GlobalPort (International) Limited. The original journal articles are an exclusive copyright of the American Diabetes Association.
This activity is supported by an educational grant from Lilly.
